Overview

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Status:
Completed

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Albumin-Bound Paclitaxel
Bevacizumab
Carboplatin
Paclitaxel